Storm Therapeutics
- Company typePrivate
- Founded2015
- HeadquartersCambridge, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Storm Therapeutics firmographics
Firmographics- Name
- Storm Therapeutics
- Legal name
- STORM Therapeutics Limited
- Website
- https://stormtherapeutics.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Storm Therapeutics industry classification
Industry- Product category
- Oncology Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Lead Optimization & Preclinical Candidate Selection (HLAIALAB)
- akta.pro secondary industry
- Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)
Keywords
Where Storm Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United Kingdom
- HQ region
- Europe
Offices2 records
Markets served
Storm Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Licensing and Milestone Payments: Pre-commercial biotech generating revenue through partnering deals. Received $17M upfront from Exelixis for ADAR1 collaboration. Eligible for development, regulatory and commercialization milestones plus tiered royalties on net sales.
- Clinical Development Partnerships: Co-development arrangements where partners provide drug supply and/or funding. Coherus provides LOQTORZI for Phase 1b/2 combination study while STORM sponsors the trial.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels5 records
Storm Therapeutics product offering
Product offeringCore offering
STORM Therapeutics develops first-in-class small-molecule drugs that inhibit RNA-modifying enzymes (RMEs) to treat cancer and other diseases. Its lead asset, STC-15, is an oral METTL3 RNA methyltransferase inhibitor currently in Phase 2 clinical development for selected sarcomas and in Phase 1b/2 combination studies with checkpoint inhibitors. The company also advances preclinical programs against METTL1 and ADAR1 through its proprietary RNA Epigenetic Platform combining mass spectrometry screening with the NASE computational algorithm.
Product overview
Storm Therapeutics is a clinical-stage biotechnology company pioneering cellular reprogramming through RNA modifications. The company's proprietary platform enables discovery of first-in-class small molecule drugs targeting RNA modifying enzymes (RMEs). Lead product STC-15 is the first RNA-modifying enzyme inhibitor to enter human clinical trials - an oral METTL3 inhibitor currently in Phase 2 for sarcoma with combination studies ongoing. The pipeline also includes METTL1 inhibitors (preclinical) and an ADAR1 inhibitor program (licensed to Exelixis).
Differentiator
Problem solved
Functional benefit
Products and services
- STC-15 First-in-class oral small-molecule inhibitor of METTL3, an RNA methyltransferase. STC-15 reprograms malignant progenitor cells by modulating mRNA methylation and is the first RNA-modifying enzyme inhibitor to enter human clinical trials, currently in Phase 2 development for select sarcomas and Phase 1b/2 combination studies with checkpoint inhibitors.
- METTL1 Inhibitor Program First-in-class small-molecule inhibitors of METTL1, a tRNA methyltransferase, for the treatment of cancer. Preclinical data demonstrates pharmacological inhibition reduces tumor growth and decreases tRNA methylation and stability of tRNAs at low nanomolar concentrations with high selectivity over other RNA and protein methyltransferases.
- ADAR1 Inhibitor Program Discovery program targeting ADAR1, an RNA-modifying enzyme involved in double-stranded RNA editing. Licensed exclusively to Exelixis for global development, manufacturing, and commercialization. ADAR1 inhibition may activate innate immune response in tumor cells and sensitize tumors to immune checkpoint inhibition, with potential applicability to up to 30% of tumors in The Cancer Genome Atlas.
- RNA Modifying Enzymes Drug Discovery Platform Proprietary drug discovery platform targeting RNA modifying enzymes for the development of novel cancer therapies. The platform enables identification of first-in-class small molecule inhibitors targeting RNA methyltransferases and other RNA-modifying enzymes including METTL3, METTL1, and ADAR1, and combines mass spectrometry-based high-throughput screening with the NASE computational algorithm.
Quantifiable outcome
- 54% disease control rate at 12 weeks in sarcoma patients with one confirmed partial response
- +4 more outcomes
Companies that use Storm Therapeutics
Customer profileNamed customers2 records
Segments2 records
Ideal customer profiles2 records
Storm Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Storm Therapeutics partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and minor.
- AlidaBiocoreStrategic collaboration using AlidaBio's EpiPlex and EpiScout NGS platforms to analyze m6A RNA modifications in clinical samples from patients treated with STC-15. Collaboration aims to identify biomarkers for patient selection by correlating m6A modification changes with clinical response.
- Coherus BioSciencescoreClinical collaboration evaluating STC-15 in combination with LOQTORZI (toripalimab-tpzi), Coherus's next-generation PD-1 inhibitor. Phase 1b/2 study in NSCLC, HNSCC, melanoma, and endometrial cancer with up to 188 patients. Coherus supplies drug; STORM sponsors trial. Each retains commercial rights to respective compounds.
- ExelixiscoreExclusive collaboration and license agreement for discovery and development of ADAR1 inhibitors and one additional undisclosed target. Exelixis paid $17M upfront, provides funding for discovery research, and is solely responsible for global development, manufacturing and commercialization. STORM eligible for development, regulatory and commercialization milestones plus tiered royalties on net sales.
- University of Cambridge (Gurdon Institute and Milner Therapeutics Institute)coreLong-standing research partnership with founding scientists Professor Tony Kouzarides and Professor Eric Miska. Collaboration with Gurdon Institute, Milner Therapeutics Institute, and Wellcome Sanger Institute on METTL3 research and drug discovery.
- Wellcome Sanger InstituteminorResearch collaboration on METTL3 inhibitor program, supported by grants from Cancer Research UK.
- University of CambridgeminorKnowledge Transfer Partnership (KTP) grant of up to £240,000 to develop analysis platform using InterMine data warehouse software for cancer research.
Scale indicators7 records
Recent moves7 records
Expansion highlights6 records
Storm Therapeutics competitors and assessment
Company assessmentEmerging players
- Hiberion (formerly Storm exited): Early-stage precision medicine company developing small molecules targeting RNA-modifying enzymes for cancer. Closely overlaps with Storm's target class and therapeutic approach but at an earlier preclinical stage.
Direct peers
- Constellation Pharmaceuticals: Developed epigenetic cancer therapies (EZH2 inhibitors) and was acquired by MorphoSys for ~$1.7B in 2021. Most relevant precedent for a clinical-stage epigenetic-modifier biotech exiting via strategic acquisition.
- Mirati Therapeutics: Clinical-stage targeted oncology company acquired by Bristol-Myers Squibb for $4.8B in 2024. Provides a relevant exit-multiple benchmark for late-stage targeted oncology biotechs with similar clinical-development profiles.
- Foghorn Therapeutics: Clinical-stage biotech developing medicines targeting the chromatin regulatory system in oncology. Operates in the same broader epigenetic drug-discovery space with comparable target-class focus and clinical-development approach.
- Epizyme: Developed TAZVERIK (tazemetostat), an EZH2 inhibitor for epithelioid sarcoma and follicular lymphoma. Closely comparable in mechanism (epigenetic modifier in oncology), sarcoma indication overlap, and clinical/regulatory pathway.
- Kronos Bio: Clinical-stage oncology company focused on targeting dysregulated transcription and chromatin signaling pathways. Comparable in stage, target-class (epigenetic/transcriptional), and clinical development strategy against transcription factor dependencies in cancer.
- Accent Therapeutics: Direct competitor developing small-molecule inhibitors of RNA-modifying enzymes (METTL3 and other targets) for cancer. Both Accent and Storm are the leading clinical-stage biotechs targeting RNA epigenetics with similar platforms and indications.
Broad incumbents
- Blueprint Medicines: Commercial-stage targeted oncology company with kinase inhibitors (avapritinib, pralsetinib). Comparable in applying structure-based drug discovery to validated oncogenic targets, providing a useful precedent for the licensing-and-partnership model Storm pursues.
Others
- Evotec: European drug-discovery platform company, partnered with Storm since 2017 on RNA-modifying enzyme drug discovery. Comparable as a CRO/platform peer with overlapping target class and adjacent drug-discovery services model.
- Exelixis: Commercial-stage oncology company that licensed Storm's ADAR1 program in 2021 ($17M upfront plus milestones). Functions as a strategic partner and acquirer-class peer representing the kind of large biotech licensing deals Storm is targeting.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
Storm Therapeutics social profiles
Digital presenceStorm Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Storm Therapeutics leadership team
Management profileNumber of profiles
Profiles17 records
Storm Therapeutics funding detail
Funding detailFunding overview
Funding rounds8 records
Investors11 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Storm Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Storm Therapeutics
What does Storm Therapeutics do?
STORM Therapeutics develops first-in-class small-molecule drugs that inhibit RNA-modifying enzymes (RMEs) to treat cancer and other diseases. Its lead asset, STC-15, is an oral METTL3 RNA methyltransferase inhibitor currently in Phase 2 clinical development for selected sarcomas and in Phase 1b/2 combination studies with checkpoint inhibitors. The company also advances preclinical programs against METTL1 and ADAR1 through its proprietary RNA Epigenetic Platform combining mass spectrometry screening with the NASE computational algorithm.
Is Storm Therapeutics a public or private company?
Storm Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Storm Therapeutics founded?
Storm Therapeutics was founded in 2015. It employs 11 to 50 people.
Where is Storm Therapeutics based?
Storm Therapeutics is headquartered in Cambridge, United Kingdom, in the Europe region.
How does Storm Therapeutics make money?
Two revenue lines are on record. Licensing and Milestone Payments are the primary driver. The others are clinical Development Partnerships.
Who are Storm Therapeutics's main competitors?
Hiberion (formerly Storm exited) is listed as an emerging player. Direct peers are Constellation Pharmaceuticals, Mirati Therapeutics, Foghorn Therapeutics, Epizyme, Kronos Bio and Accent Therapeutics. Blueprint Medicines is listed as a broad incumbent. Others are Evotec and Exelixis.
Does Storm Therapeutics have an API?
No public API is recorded for Storm Therapeutics.
What industry is Storm Therapeutics in?
Storm Therapeutics's product category is Oncology Therapeutics. Its primary akta.pro industry code is HLAIALAB, Lead Optimization & Preclinical Candidate Selection, with a secondary code of HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 541714 and its SIC code is 8731.